Stock Watch: AstraZeneca’s Third-Quarter Crescendo
Big Pharma Earnings Season Ends With A Knock-Out Report
Executive Summary
In a third-quarter earnings report that was difficult to fault AstraZeneca left big pharma earnings season on a high note. But raised full-year guidance depends on Evusheld sales and maybe China.